ZA200603522B - Vaccine composition admixed with an alkylphosphatidylcholine - Google Patents
Vaccine composition admixed with an alkylphosphatidylcholine Download PDFInfo
- Publication number
- ZA200603522B ZA200603522B ZA200603522A ZA200603522A ZA200603522B ZA 200603522 B ZA200603522 B ZA 200603522B ZA 200603522 A ZA200603522 A ZA 200603522A ZA 200603522 A ZA200603522 A ZA 200603522A ZA 200603522 B ZA200603522 B ZA 200603522B
- Authority
- ZA
- South Africa
- Prior art keywords
- vaccine
- composition
- phosphatidylcholine
- acid
- administered
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims description 22
- 239000000427 antigen Substances 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 150000008105 phosphatidylcholines Chemical class 0.000 claims abstract description 7
- 239000012646 vaccine adjuvant Substances 0.000 claims abstract description 4
- 229940124931 vaccine adjuvant Drugs 0.000 claims abstract description 4
- -1 ester derivative of phosphatidylcholine Chemical class 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- 235000021313 oleic acid Nutrition 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- 150000002430 hydrocarbons Chemical class 0.000 claims 3
- 150000002148 esters Chemical class 0.000 abstract description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002423 protozoacide Substances 0.000 abstract 1
- 230000001549 tubercolostatic effect Effects 0.000 abstract 1
- 239000000814 tuberculostatic agent Substances 0.000 abstract 1
- 239000012873 virucide Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000000899 immune system response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101710085465 Alpha-tubulin N-acetyltransferase 2 Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0313406A FR2862306B1 (fr) | 2003-11-17 | 2003-11-17 | Composition vaccinale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200603522B true ZA200603522B (en) | 2007-07-25 |
Family
ID=34508504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200603522A ZA200603522B (en) | 2003-11-17 | 2004-11-15 | Vaccine composition admixed with an alkylphosphatidylcholine |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7344720B2 (lt) |
| EP (1) | EP1696954B1 (lt) |
| JP (1) | JP4638880B2 (lt) |
| KR (1) | KR101136107B1 (lt) |
| CN (1) | CN1882358B (lt) |
| AT (1) | ATE412429T1 (lt) |
| AU (1) | AU2004290943B2 (lt) |
| BR (1) | BRPI0416670A (lt) |
| CA (1) | CA2545086C (lt) |
| CY (1) | CY1108498T1 (lt) |
| DE (1) | DE602004017504D1 (lt) |
| DK (1) | DK1696954T3 (lt) |
| ES (1) | ES2311875T3 (lt) |
| FR (1) | FR2862306B1 (lt) |
| IL (1) | IL175573A (lt) |
| LT (1) | LT5435B (lt) |
| LV (1) | LV13457B (lt) |
| NO (1) | NO20062779L (lt) |
| PL (1) | PL1696954T3 (lt) |
| PT (1) | PT1696954E (lt) |
| SI (1) | SI1696954T1 (lt) |
| WO (1) | WO2005049080A1 (lt) |
| ZA (1) | ZA200603522B (lt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100752990B1 (ko) * | 2006-08-02 | 2007-08-30 | 주식회사 대웅 | 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물 |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| WO2009109550A1 (en) | 2008-03-05 | 2009-09-11 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
| EP2430151B1 (fr) | 2009-05-14 | 2014-06-18 | Sanofi Pasteur | Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6 |
| EP2429659B1 (fr) * | 2009-05-14 | 2017-12-13 | Sanofi Pasteur | Procédé de détoxification du lipopolysaccharide (lps) ou du lipide a des bactéries à gram-négatif |
| WO2010130896A2 (fr) | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif |
| EP2578974A1 (en) | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Process line for the production of freeze-dried particles |
| JP5761143B2 (ja) * | 2011-11-02 | 2015-08-12 | 株式会社リコー | 撮像ユニット、撮像ユニットを搭載した車両 |
| US20140147475A1 (en) * | 2012-11-29 | 2014-05-29 | Antonius Arnoldus Christiaan Jacobs | Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida |
| MX357432B (es) | 2013-03-18 | 2018-07-09 | Intervet Int Bv | Vacuna para proteger a un rumiante contra la neumonia causada por mannheimia haemolytica. |
| CN107073350B (zh) | 2014-07-21 | 2019-11-15 | 赛诺菲巴斯德股份公司 | 用于产生液滴的液体给送装置 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| FR2773156B1 (fr) | 1997-12-26 | 2000-03-31 | Biovacs Inc | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida |
| DE60118228T2 (de) | 2000-09-28 | 2006-12-14 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Mikropartikel zur verabreichung von heterologen nukleinsäure |
| AU1486102A (en) * | 2000-11-07 | 2002-05-21 | Immunovaccine Technologies Inc | Vaccines with enhanced immune response and methods for their preparation |
| US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
-
2003
- 2003-11-17 FR FR0313406A patent/FR2862306B1/fr not_active Expired - Fee Related
-
2004
- 2004-11-15 US US10/989,154 patent/US7344720B2/en not_active Expired - Fee Related
- 2004-11-15 CA CA 2545086 patent/CA2545086C/en not_active Expired - Fee Related
- 2004-11-15 ES ES04805451T patent/ES2311875T3/es not_active Expired - Lifetime
- 2004-11-15 KR KR1020067009520A patent/KR101136107B1/ko not_active Expired - Fee Related
- 2004-11-15 BR BRPI0416670 patent/BRPI0416670A/pt not_active IP Right Cessation
- 2004-11-15 EP EP04805451A patent/EP1696954B1/fr not_active Expired - Lifetime
- 2004-11-15 CN CN2004800338756A patent/CN1882358B/zh not_active Expired - Fee Related
- 2004-11-15 SI SI200430990T patent/SI1696954T1/sl unknown
- 2004-11-15 AU AU2004290943A patent/AU2004290943B2/en not_active Ceased
- 2004-11-15 PT PT04805451T patent/PT1696954E/pt unknown
- 2004-11-15 WO PCT/FR2004/002911 patent/WO2005049080A1/fr not_active Ceased
- 2004-11-15 ZA ZA200603522A patent/ZA200603522B/en unknown
- 2004-11-15 DK DK04805451T patent/DK1696954T3/da active
- 2004-11-15 AT AT04805451T patent/ATE412429T1/de active
- 2004-11-15 JP JP2006540508A patent/JP4638880B2/ja not_active Expired - Fee Related
- 2004-11-15 DE DE200460017504 patent/DE602004017504D1/de not_active Expired - Lifetime
- 2004-11-15 PL PL04805451T patent/PL1696954T3/pl unknown
-
2006
- 2006-05-11 IL IL175573A patent/IL175573A/en active IP Right Grant
- 2006-05-15 LV LVP-06-70A patent/LV13457B/lv unknown
- 2006-05-17 LT LT2006036A patent/LT5435B/lt not_active IP Right Cessation
- 2006-06-14 NO NO20062779A patent/NO20062779L/no not_active Application Discontinuation
-
2008
- 2008-01-09 US US11/971,751 patent/US7767658B2/en not_active Expired - Fee Related
- 2008-11-11 CY CY081101283T patent/CY1108498T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7767658B2 (en) | Vaccine composition | |
| Tretiakova et al. | Liposomes as adjuvants and vaccine delivery systems | |
| US20070298093A1 (en) | Synergistic Liposomal Adjuvants | |
| US4196191A (en) | Biological preparations | |
| CA2549114C (en) | Immunostimulant composition comprising at least one toll-like 7 receptor or toll-like 8 receptor agonist and a toll-like 4 receptor agonist | |
| JP2002500165A (ja) | 新規の重合性の脂肪酸、リン脂質、及びそれから得られた重合リポソーム | |
| US4148876A (en) | Biological preparations | |
| CN108324938A (zh) | 一种颗粒型佐剂及其制备方法和应用 | |
| EP2543387A1 (en) | Mucosal vaccine | |
| GB1564500A (en) | Biological preparations | |
| EP1064950A1 (en) | Remedies for hepatitis | |
| JP7082110B2 (ja) | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット | |
| CN118045169A (zh) | 脂质-带电分子偶联物、可吸入式脂质纳米颗粒及其制备方法和应用 | |
| MXPA06005486A (es) | Composicion de vacuna mezclada con una alquilfosfatidilcolina | |
| Gregoriadis et al. | Medical Research Council Group, Academic Department of Medicine, Royal Free Hospital School of Medicine, Pond Street | |
| Hölig | Keywords Phospholipids Vaccines Depot injectables Pulmonary dosage forms Natural and Synthetic Phospholipids For Vaccines and Other Complex Drug Delivery Systems–Part 1 Dr. Richard Wibel, PD Dr. Peter van Hoogevest 2, Dr. Peter Hölig· Lipoid GmbH, Ludwigshafen am Rhein; 2· PHARMANOVATION Consulting, Rheinfelden (Baden) | |
| MXPA06006958A (es) | Composicion inmunoestimuladora que comprende al menos un receptor y similar a toll o agonista de receptor 8 similar a toll y un agonista de receptor 4 similar a toll | |
| HK1026613B (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a | |
| HK1026613A1 (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |